Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 17, 2026 | June 22, 2026 |
| Aravive, Inc.ARAV · Entity 114535 | Director | September 23, 2022 | September 26, 2022 |
| Whitehawk Therapeutics, Inc.ARPO · Entity 6074 | See Remarks | May 14, 2019 | May 16, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 197,429 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 35,700 · Balance 197,429 F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2036-06-17 | Direct | 53,600 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 53,600 · Balance 53,600 F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Aravive, Inc.
Report date September 23, 2022 · Filed September 26, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.92 · Expires 2032-09-22 | Direct | 97,063 |
Reported balance
After 2022-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-23 · Grant · Acquired 97,063 · Balance 97,063 F1: These options vest pro rata on a monthly basis commencing on October 23,2022 for the next 12 months with full vesting, if not fully vested at such time, on the date of Aravive, Inc.'s next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest pro rata on a monthly basis commencing on October 23,2022 for the next 12 months with full vesting, if not fully vested at such time, on the date of Aravive, Inc.'s next annual meeting of stockholders.
Whitehawk Therapeutics, Inc.
Report date May 14, 2019 · Filed May 16, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2029-05-14 | Direct | 169,500 |
Reported balance
After 2019-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-14 · Grant · Acquired 169,500 · Balance 169,500 F1: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2029-05-14 | Direct | 430,500 |
Reported balance
After 2019-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-14 · Grant · Acquired 430,500 · Balance 430,500 F2: 50% of the shares shall vest on June 30, 2020 and the remaining 50% shall vest on June 30, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date.
F2: 50% of the shares shall vest on June 30, 2020 and the remaining 50% shall vest on June 30, 2021.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EyePoint, Inc.
Report date June 25, 2019 · Filed June 27, 2019
Section 16 reporting ended · disclosed 2019-06-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2020-06-25 | Direct | 40,000 |
Reported balance
After 2019-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-25 · Grant · Acquired 40,000 · Balance 40,000 F1: Reflects the closing price of the Company's common stock on February 21, 2019, which was the date the option grant was approved by the Compensation Committee of the Board of Directors (the "Committee") of EyePoint Pharmaceuticals, Inc. (the "Registrant"), subject to stockholder approval of an amendment to the Registrant's 2016 Long Term Incentive Plan (the "Plan Amendment"). F2: The option grant was approved by the Committee on February 21, 2019, subject to stockholder approval of the Plan Amendment. The Registrant's stockholders approved the Plan Amendment on June 25, 2019. F3: The option to purchase, which vested immediately upon Mr. Rogers' departure from the Board, will be exercisable until June 25, 2020 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the closing price of the Company's common stock on February 21, 2019, which was the date the option grant was approved by the Compensation Committee of the Board of Directors (the "Committee") of EyePoint Pharmaceuticals, Inc. (the "Registrant"), subject to stockholder approval of an amendment to the Registrant's 2016 Long Term Incentive Plan (the "Plan Amendment").
F2: The option grant was approved by the Committee on February 21, 2019, subject to stockholder approval of the Plan Amendment. The Registrant's stockholders approved the Plan Amendment on June 25, 2019.
F3: The option to purchase, which vested immediately upon Mr. Rogers' departure from the Board, will be exercisable until June 25, 2020
KERYX BIOPHARMACEUTICALS INC
Report date December 12, 2018 · Filed December 13, 2018
Section 16 reporting ended · disclosed 2018-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-12 transaction · row 1
1 source rowRow 1 · 2018-12-12 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 19,999 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. |
| Stock OptionSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-12 · Disposition to issuer · Disposed 140,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement.
F2: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 19,999 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018.
F3: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:22 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 53,600 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001244159-26-000001 · primarydocument.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,600 Underlying: Common Stock · 53,600 shares Expires 2036-06-17 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:22 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 35,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001244159-26-000001 · primarydocument.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,429 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:14 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 53,600 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001562180-25-004720 · primarydocument.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,600 Underlying: Common Stock · 53,600 shares Expires 2035-06-10 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:14 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 35,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004720 · primarydocument.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,729 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:19 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 45,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001562180-24-004907 · primarydocument.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-06 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:19 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004907 · primarydocument.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,029 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Third Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 45,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001562180-23-004959 · primarydocument.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-06-06 F2 · derivative.exercise_date: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:08 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-004959 · primarydocument.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,029 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Second Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| September 23, 2022 Filed Sep 26, 2022 20:07 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option (Right to Buy) · Derivative | 97,063 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001437749-22-023060 · rdgdoc.xml · derivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,063 Underlying: Common Stock · 97,063 shares Expires 2032-09-22 F1 · derivative.exercise_date: These options vest pro rata on a monthly basis commencing on October 23,2022 for the next 12 months with full vesting, if not fully vested at such time, on the date of Aravive, Inc.'s next annual meeting of stockholders. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 20:58 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001562180-22-004976 · primarydocument.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2032-06-08 F2 · shares: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 20:58 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-004976 · primarydocument.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,029 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 20:06 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 22,812 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001437749-21-022011 · rdgdoc.xml · derivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,812 Underlying: Common Stock · 22,812 shares Expires 2031-09-09 F1 · derivative.exercise_date: These options vest pro rata on a monthly basis commencing on October 10, 2021 for the next 12 months with full vesting, if not fully vested at such time, on the date of Aravive, Inc.'s next annual meeting of stockholders. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 21:27 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001562180-21-004029 · primarydocument.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2031-06-02 F2 · shares: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 21:27 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004029 · primarydocument.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,329 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 11:06 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 14,987 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0000899243-20-025488 · doc4.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,987 Underlying: Common Stock · 14,987 shares Expires 2030-09-14 F2 · derivative.exercise_date: These option vest 1/36th per month. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 11:06 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 15,024 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0000899243-20-025488 · doc4.xml · derivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,024 Underlying: Common Stock · 15,024 shares Expires 2030-09-14 F1 · derivative.exercise_date: These options vest pro rata on a monthly basis commencing on October 15, 2020 for the next 12 months with full vesting, if not fully vested at such time, on the date of Aravive, Inc.'s next annual meeting of stockholders. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:17 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $11.96 | $0.00 |
DisclosureSEC source: 0001562180-20-004357 · primarydocument.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2030-06-05 F2 · shares: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:17 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-004357 · primarydocument.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,629 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001562180-19-003669 · primarydocument.xml · derivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2020-06-25 F1 · derivative.exercise_price: Reflects the closing price of the Company's common stock on February 21, 2019, which was the date the option grant was approved by the Compensation Committee of the Board of Directors (the "Committee") of EyePoint Pharmaceuticals, Inc. (the "Registrant"), subject to stockholder approval of an amendment to the Registrant's 2016 Long Term Incentive Plan (the "Plan Amendment"). F2 · date: The option grant was approved by the Committee on February 21, 2019, subject to stockholder approval of the Plan Amendment. The Registrant's stockholders approved the Plan Amendment on June 25, 2019. F3 · derivative.exercise_date: The option to purchase, which vested immediately upon Mr. Rogers' departure from the Board, will be exercisable until June 25, 2020 F3 · derivative.expiration_date: The option to purchase, which vested immediately upon Mr. Rogers' departure from the Board, will be exercisable until June 25, 2020 Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 20:31 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionDeferred Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003630 · primarydocument.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.exercise_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.expiration_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 20:31 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003630 · primarydocument.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company"). Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001562180-19-003439 · primarydocument.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2029-06-06 F2 · shares: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003439 · primarydocument.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,929 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 14, 2019 Filed May 16, 2019 21:14 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 430,500 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0000899243-19-013767 · doc4.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,500 Underlying: Common Stock · 430,500 shares Expires 2029-05-14 F2 · derivative.exercise_date: 50% of the shares shall vest on June 30, 2020 and the remaining 50% shall vest on June 30, 2021. Read SEC document |
| May 14, 2019 Filed May 16, 2019 21:14 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 169,500 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0000899243-19-013767 · doc4.xml · derivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,500 Underlying: Common Stock · 169,500 shares Expires 2029-05-14 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:51 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 215,328 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0000899243-19-004271 · doc4.xml · derivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,328 Underlying: Common Stock · 215,328 shares Expires 2029-02-15 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the grant date and an additional 1/48th monthly thereafter until the fourth anniversary of the grant date. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 16:40 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | Disposition to issuerStock Option · Derivative | 140,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030894 · doc4.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,000 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. F3 · price: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into an option to acquire Akebia common stock, with the number of shares and exercise price adjusted for the Exchange Ratio in accordance with the terms of the Merger Agreement. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 16:40 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | Disposition to issuerCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030894 · doc4.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2 · shares: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 19,999 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated June 28, 2018, by and between Keryx Biopharmaceuticals, Inc. ("Keryx"), Akebia Therapeutics, Inc. ("Akebia") and Alpha Therapeutics Merger Sub Inc., as amended on October 1, 2018 (the "Merger Agreement"), whereby each share of common stock of Keryx was canceled and automatically converted into 0.37433 shares of common stock of Akebia (the "Exchange Ratio"), with fractional shares being paid in cash as provided in the Merger Agreement. F2 · price: (Continued from footnote 1) The market value of each share of Akebia common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Includes 19,999 shares of restricted stock, the vesting of which was accelerated as a result of the Merger, and each share of restricted stock was cancelled and converted into the right to receive 0.37433 shares of Akebia common stock, with fractional shares being paid in cash. The market value of each share of Akebia common stock received is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 23:44 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0000899243-18-030951 · doc4.xml · derivative · entry 6 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-12-12 F4 · derivative.exercise_date: 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 23:44 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 11,229 | Not disclosed Strike: $10.05 | Not disclosed |
DisclosureSEC source: 0000899243-18-030951 · doc4.xml · derivative · entry 5 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,229 Underlying: Common Stock · 11,229 shares Expires 2028-06-30 F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent. F2 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 23:44 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 11,229 | Not disclosed Strike: $17.53 | Not disclosed |
DisclosureSEC source: 0000899243-18-030951 · doc4.xml · derivative · entry 4 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,229 Underlying: Common Stock · 11,229 shares Expires 2027-06-09 F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent. F2 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 23:44 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 11,229 | Not disclosed Strike: $15.26 | Not disclosed |
DisclosureSEC source: 0000899243-18-030951 · doc4.xml · derivative · entry 3 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,229 Underlying: Common Stock · 11,229 shares Expires 2026-05-26 F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent. F2 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 23:44 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 18,716 | Not disclosed Strike: $12.48 | Not disclosed |
DisclosureSEC source: 0000899243-18-030951 · doc4.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,716 Underlying: Common Stock · 18,716 shares Expires 2026-03-31 F3 · price: Pursuant to the Merger Agreement, each option to purchase Keryx common stock (a "Keryx Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares subject to such Keryx Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Multiplier, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Keryx Option by the Exchange Multiplier, rounded up to the nearest whole cent. F2 · derivative.exercise_date: The option is fully vested and currently exercisable. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 23:44 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 11,229 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030951 · doc4.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,229 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018 (as amended, the "Merger Agreement"), each share of common stock of Keryx Biopharmaceuticals, Inc. ("Keryx") owned by the Reporting Person at the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time") was automatically converted into 0.37433 shares of the Issuer's common stock (the "Exchange Multiplier"). Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 21:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0000899243-18-029124 · doc4.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2018-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2018 Filed Nov 16, 2018 21:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 100,000 | $1.13 | $113,000.00 |
DisclosureSEC source: 0000899243-18-029124 · doc4.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Consists of (i) 100,000 shares of common stock, par value $0.001 per share, of EyePoint Pharmaceuticals, Inc. (the "Company") acquired upon exercise of the stock option as described above and (ii) 12,500 shares of common stock of the Company underlying certain deferred stock units ("DSUs") previously awarded to the reporting person, with each DSU representing the right to receive one share of common stock of the Company. These DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, Read SEC document |
| June 30, 2018 Filed Jul 12, 2018 18:01 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantStock Options (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001114220-18-000078 · wf-form4_153143285173847.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-30 F3 · derivative.exercise_date: The 30,000 stock options vest as to one-third on each of June 30, 2019, June 30, 2020 and June 30, 2021. Read SEC document |
| June 30, 2018 Filed Jul 12, 2018 18:01 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001114220-18-000078 · wf-form4_153143285173847.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: The 10,000 shares are restricted common stock, with one-third of the 10,000 shares vesting on each of June 30, 2019, June 30, 2020 and June 30, 2021. F2 · balance_after: Includes 19,999 shares of restricted stock. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionDeferred Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-018709 · doc4.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.exercise_date: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.expiration_date: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 20:00 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-018709 · doc4.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company"). Read SEC document |
| June 21, 2018 Filed Jun 26, 2018 18:12 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantDeferred Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-018096 · doc4.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company"). F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document |
| June 21, 2018 Filed Jun 26, 2018 18:12 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantEmployee Stock Option (right to buy) · Derivative | 26,667 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0000899243-18-018096 · doc4.xml · derivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,667 Underlying: Common Stock · 26,667 shares Expires 2028-06-21 Read SEC document |
| April 23, 2018 Filed Apr 26, 2018 00:24 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 144,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0000899243-18-010747 · doc4.xml · derivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 Underlying: Common Stock · 144,000 shares Expires 2028-04-23 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the vesting start date and an additional 1/48th monthly thereafter until the fourth anniversary of the vesting start date. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 21:08 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantDeferred Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-029160 · doc4.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of pSivida Corp. (the "Company"). F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 21:08 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0000899243-17-029160 · doc4.xml · derivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-27 Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 22:06 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 293,006 | $5.50 Strike: $5.50 | $1,611,533.00 |
DisclosureSEC source: 0000899243-17-029052 · doc4.xml · derivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 293,006 shares Expires 2027-11-15 F1 · derivative.exercise_date: Options exercisable as to 1/4th on the first anniversary of the vesting start date and an additional 1/48th monthly thereafter until the fourth anniversary of the vesting start date Read SEC document |
| June 09, 2017 Filed Jun 20, 2017 16:06 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantStock Options (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0000899243-17-016756 · doc4.xml · derivative · entry 2 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-06-09 F3 · derivative.exercise_date: The 30,000 stock options vest as to one-third on each of June 9, 2018, June 9, 2019 and June 9, 2020. Read SEC document |
| June 09, 2017 Filed Jun 20, 2017 16:06 UTC | KERYX BIOPHARMACEUTICALS INC KERX · Entity 161794 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-016756 · doc4.xml · nonDerivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: The 10,000 shares are restricted common stock, with one-third of the 10,000 shares vesting on each of June 9, 2018, June 9, 2019 and June 9, 2020. F2 · balance_after: Includes 16,666 shares of restricted stock. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 18:02 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0000899243-16-035517 · doc4.xml · derivative · entry 1 ROGERS MICHAEL W · CIK 0001244159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-07-21 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.